Hidden evidence in Kaiser Black tech IP theft

Black Innovators’ Struggle: ViQUAL’s IP Theft Case

By Darius Spearman (africanelements)

Support African Elements at patreon.com/africanelements and hear recent news in a single playlist. Additionally, you can gain early access to ad-free video content.

ViQUAL’s Appeal: A Black Firm’s IP Theft Battle

The fight for recognition and justice continues for ViQUAL Medical Technology, a Black-owned biotech company making headlines. They have filed an appeal in a significant legal case against healthcare giant Kaiser Permanente. ViQUAL alleges the theft of its valuable intellectual property and trade secrets. This isn’t just another corporate lawsuit; indeed, it shines a light on the tough road Black innovators often travel in the healthcare and biotech industries (Black News).

The stakes are incredibly high. The case’s value is estimated to be between $900 million and over $1.5 billion. This wide range depends on estimated profits from 2012 to 2025 and future projections. Beyond the monetary figures, however, ViQUAL’s appeal underscores systemic issues. These issues frequently hinder Black entrepreneurs and inventors. Their journey highlights a broader call for fairness and equity within these influential sectors (Black News).

The Alleged Betrayal: Stolen Ideas and Concealed Evidence in IP Theft Case

ViQUAL Medical Technology’s allegations against Kaiser Permanente are serious. They accuse Kaiser of stealing intellectual property and trade secrets. Furthermore, ViQUAL claims Kaiser engaged in corporate exploitation of the legal system. The company states that Kaiser Permanente concealed crucial evidence. This evidence includes an enabled badge and a wearable wristband, items central to ViQUAL’s innovations and the case itself (Black News).

Adding to their claims, ViQUAL asserts that the court overlooked video evidence supporting their position. The company believes these materials are vital. They could demonstrate the alleged misuse of their proprietary technology. The appeal seeks to bring this overlooked evidence to the forefront. Consequently, ViQUAL hopes for a re-evaluation of the case’s merits in light of all available information (Black News).

Justice Denied? The Initial $900M Lawsuit Dismissal in Legal Battle

The legal journey for ViQUAL has been long and challenging. After more than five years of litigation, a California state judge delivered a setback. The judge ruled there was no evidence that Kaiser Permanente took or used confidential information. This decision led to the dismissal of ViQUAL’s initial $900 million trade secrets lawsuit (Wearable tech company fails to land $900m trade secrets suit; Law360).

This dismissal was undoubtedly a significant blow to the Black-owned tech company. However, ViQUAL maintains that key evidence was not adequately considered. The appeal represents their continued fight. They believe a fair review of all facts, including the allegedly concealed and overlooked materials, will lead to a different outcome. This persistence underscores the difficulties faced when smaller innovators take on large corporations, particularly when systemic biases may be at play.

Beyond the Courtroom: Systemic Racism in Biotech Affects Black Innovators

The ViQUAL case does not exist in a vacuum. It highlights systemic issues that Black innovators often face in the biotech and healthcare sectors. These sectors struggle with a lack of diversity and opportunity. Racism and structural barriers can prevent talented individuals from succeeding. These challenges can appear as underrepresentation in the workforce. They also manifest as unequal access to funding and biased treatment in legal and business dealings (Black News).

Statistics paint a stark picture. For example, Black Americans comprise only 6% of the life sciences workforce (BioSpace). This underrepresentation is not accidental. It stems from systemic racism that affects education and career paths for Black students. Moreover, structural racism impacts healthcare delivery itself. This can lead to poorer clinical care for people of color and create a two-tier healthcare system (STAT News). Such disparities also affect innovation equity and health outcomes, making the fight for fair treatment even more critical (Innovators Magazine).

The Price of Innovation: Valuing ViQUAL’s Claim in the IP Theft Case

The financial dimensions of the ViQUAL versus Kaiser Permanente case are substantial. The claim’s valuation, ranging from $900 million to over $1.5 billion, reflects the potential profits ViQUAL believes it lost. These figures are based on estimated earnings spanning from 2012 through 2025. Additionally, they include projections for future income if the alleged intellectual property theft had not occurred (Black News).

For a Black-owned biotech company like ViQUAL, such losses can be devastating. They represent financial harm and the derailment of innovation and market opportunity. The lawsuit, therefore, is about more than money. It is about the right to compete fairly. It is also about protecting the fruits of one’s labor and ingenuity, especially for minority-led enterprises that often face greater hurdles in securing their place in the market.

Kaiser Permanente: A Pattern of Accountability Questions?

While ViQUAL battles Kaiser Permanente over intellectual property, Kaiser has faced scrutiny in other areas. For instance, the California Department of Managed Health Care (DMHC) fined Kaiser Permanente $819,500 for failing to handle member complaints in a timely manner. Specifically, the DMHC cited Kaiser for not processing 61 complaints within the required timeframes (DMHC).

Such incidents raise questions about corporate accountability. While the DMHC fine is separate from the ViQUAL case, it contributes to a broader picture of how large organizations operate and are held responsible. For communities that often feel overlooked or mistreated by large institutions, these issues resonate deeply. Therefore, ViQUAL’s fight for its intellectual property occurs within a context where concerns about corporate practices and fairness are already present.

The Fight Continues: ViQUAL’s Pursuit of a Fair Hearing in Legal Battle

ViQUAL Medical Technology is not backing down. The company’s appeal aims to revisit the original court decision. They argue that crucial evidence, including video footage, was overlooked. This evidence, ViQUAL contends, is vital to proving their claims of intellectual property theft and trade secret misuse by Kaiser Permanente (Black News). The appeal process offers a chance for this evidence to be thoroughly examined.

The outcome of this appeal could have far-reaching implications. A successful appeal for ViQUAL might bring them the justice they seek and send a message. It could highlight the importance of due diligence and fairness in legal proceedings involving minority innovators. Conversely, the struggle itself, regardless of the outcome, already underscores the significant challenges Black-owned businesses can face when protecting their innovations against powerful entities.

ABOUT THE AUTHOR

Darius Spearman has been a professor of Black Studies at San Diego City College since 2007. He is the author of several books, including Between The Color Lines: A History of African Americans on the California Frontier Through 1890. You can visit Darius online at africanelements.org.